Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Medicine type
Approval status
AllApproved in the United States (FDA)Approved in the European Union (EMA)In Phase 3 testingIn Phase 2 testingUsed in a way not covered by an approval, or made by a compounding pharmacyDietary supplement; not FDA-approved as a medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Laboratory or animal-stage researchControlled substance; no approved US useWithdrawn from the market
Amount of information
Showing 1–2 of 2 records
Ipamorelin (Also written NNC 26-0161. No trade name; never marketed)
Peptide medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
A growth hormone releaser designed to leave cortisol alone — never approved
CJC-1295 (CJC-1295 with DAC. The product sold as "CJC-1295 without DAC" is a different molecule, modified GRF(1-29))
Peptide medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Raises growth hormone for a week per injection — no approved use anywhere